Navigation Links
SciClone To Present At 2015 Aegis Capital Growth Conference On October 9th
Date:9/30/2015

FOSTER CITY, Calif., Sept. 30, 2015 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Wilson W. Cheung, Chief Financial Officer, will present a corporate overview and business update at the 2015 Aegis Capital Growth Conference at 11:25 am PT on Friday, October 9, 2015, at The Encore at Wynn Las Vegas.  

To access the live audio webcast of these presentations, please log on through a link located in the Investor Relations section of SciClone's website at www.sciclone.com, under the Calendar of Events tab. A replay of the webcast will be available one hour after the conclusion of the live events.

About SciClone SciClone Pharmaceuticals is a revenue-generating, specialty pharmaceutical company with a substantial commercial business in China and a product portfolio spanning major therapeutic markets including oncology, infectious diseases and cardiovascular disorders. SciClone's proprietary lead product, ZADAXIN® (thymalfasin), is approved in over 30 countries and may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV), and certain cancers, and as a vaccine adjuvant, according to the local regulatory approvals. The Company has successfully in-licensed and commercialized products with the potential to become future market leaders and to drive the Company's long-term growth, including DC Bead®, a novel treatment for liver cancer. Through its promotion business with pharmaceutical partners, SciClone also markets multiple branded products in China which are therapeutically differentiated. SciClone is a publicly-held corporation based in Foster City, California, and trades on the NASDAQ Global Select Market under the symbol SCLN. For additional information, please visit www.sciclone.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding expected financial results and expectations. Readers are urged to consider statements that include the words "may," "will," "would," "could," "should," "might," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," "unaudited," "approximately" or the negative of those words or other comparable words to be uncertain and forward-looking. These statements are subject to risks and uncertainties that are difficult to predict and actual outcomes may differ materially.  Please also refer to other risks and uncertainties described in SciClone's filings with the SEC. All forward-looking statements are based on information currently available to SciClone and SciClone assumes no obligation to update any such forward-looking statements.

SciClone, SciClone Pharmaceuticals, the SciClone Pharmaceuticals design, the SciClone logo and ZADAXIN are registered trademarks of SciClone Pharmaceuticals, Inc. in the United States and numerous other countries.Corporate ContactsWilson W. CheungJane GreenChief Financial OfficerInvestors/Media650.358.3434650.358.1447wcheung@sciclone.comjgreen@sciclone.comLogo - http://photos.prnewswire.com/prnh/20150722/240358LOGO

 


'/>"/>
SOURCE SciClone Pharmaceuticals, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. SciClone To Present At Two Investor Conferences On September 10, 2015
2. Cumberland Pharmaceuticals To Present At The UBS Global Healthcare Conference In New York
3. Bayer to Present New Data Across Oncology Portfolio at ASCO 2013
4. Arno Therapeutics to Present Positive, New Data Supporting the Potential of Onapristone in Endometrial and Breast Cancers at ASCO 2013 Annual Meeting
5. ASCO 2013: Boehringer Ingelheim to Present Data Across Multiple Cancers, Including Different Treatment Settings for Advanced NSCLC
6. Boehringer Ingelheim Presents Progression-Free Survival Data for Investigational Afatinib and Nintedanib in Advanced NSCLC
7. Amgen Highlights Data To Be Presented At American Society of Clinical Oncology Annual Meeting
8. AbbVie to Present Data on Investigational Anti-Cancer Compounds at American Society of Clinical Oncology Annual Meeting
9. Asmacure to Present Four Posters on Novel Pulmonary Development Compound ASM-024 at American Thoracic Society 2013 International Conference
10. Actinium Pharmaceuticals Clinical Results to be Presented at 8th International Symposium on Targeted Alpha Therapy Conference
11. AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2020)... MOBILE, Ala. (PRWEB) , ... March 30, 2020 ... ... solutions company, is launching a new solution, TalkWithYourDoc.com . By leveraging ... solution enables providers of all sizes to continue offering revenue-generating healthcare services while ...
(Date:3/30/2020)... ... March 30, 2020 , ... “In the ... continuity. Unfortunately, we hear stories from our customers of vendor price-gouging. We are ... advantage of people’s hardships in this difficult time,” says Borya Shakhnovich, CEO of ...
(Date:3/28/2020)... ... March 27, 2020 , ... Known for bridging the gap between ... launched a new hand sanitizer in response to the COVID-19 outbreak. , As hand ... continue to expand during the next several months even in the absence of the ...
Breaking Medicine Technology:
(Date:3/28/2020)... ... March 27, 2020 , ... Suntuity AirWorks ( https://suntuityairworks.com ), ... mobilizing their drone equipment and training personnel to help towns and cities combat ... Matrice and Agras drones, Suntuity AirWorks is mobilizing their drone equipment and services ...
(Date:3/28/2020)... ... March 27, 2020 , ... The construction industry is taking ... the coronavirus. Operating under the designation as an essential business as modified today ... protection projects in the downstate New York region. , While certain projects have ...
(Date:3/28/2020)... ... March 27, 2020 , ... Ahead of ... March’s edition of “The Fertility Journey.” This campaign will serve as a guide, ... and maternal health options. , One in 6 couples experiences trouble with ...
(Date:3/28/2020)... (PRWEB) , ... March 28, 2020 , ... ... Paso Physical Therapy Services (EPPTS), a physical therapist-owned rehabilitation company since 1985 specializing ... El Paso, TX. , “Since we started more than 30 years ago, we ...
(Date:3/27/2020)... MARY, Fla. (PRWEB) , ... March 27, 2020 , ... ... three-month online educational health conference for people with asthma, their families and caregivers living ... a day between March 27, 2020 and June 30, 2020, and will focus on ...
Breaking Medicine News(10 mins):